|

Disitamab Vedotin(RC48) Plus Tratuzumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Zhejiang Cancer Hospital1

Indications

  • HER2-positive Gastroesophageal Junction Adenocarcinoma1
  • HER2-positive Gastric Cancer1
  • Cancer1

Other1 trial

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.